Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Foundation Medicine Inc | 84 |
| 2 | Gilead Sciences Inc | 83 |
| 3 | Chugai Pharmaceutical Co Ltd | 69 |
| 4 | F Hoffmann La Roche AG | 28 |
| 5 | Cincinnati Children's Hospital Medical Center | 25 |
| 6 | The University of Texas System | 23 |
| 7 | United States Department of Health and Human Services | 22 |
| 8 | The University of Texas at Austin | 20 |
| 9 | North Carolina State University | 17 |
| 10 | Genentech Inc | 16 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 882 |
| 2 | A61P | Therapeutic activity (drug indications) | 861 |
| 3 | C07K | Peptides | 350 |
| 4 | C07D | Heterocyclic compounds | 320 |
| 5 | C12N | Microorganisms, enzymes | 197 |
| 6 | C12Q | Measuring/testing involving enzymes | 190 |
| 7 | G16B | 142 | |
| 8 | G01N | Investigating / analysing materials | 138 |
| 9 | G16H | Digital health, healthcare informatics | 91 |
| 10 | Y02A | Climate change adaptation | 53 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Lung Cancer Treatments and Mutations | 8 |
| 2 | Heat shock proteins research | 1 |
| 3 | Salivary Gland Tumors Diagnosis and Treatment | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Peter N. Morcos | Roche (United States) | 17 |
| 2 | Alice T. Shaw | Massachusetts General Hospital | 18 |
| 3 | Bogdana Balas | Roche (Switzerland) | 12 |
| 4 | D. Ross Camidge | University of Colorado Denver | 12 |
| 5 | Makoto Nishio | Japanese Foundation For Cancer Research | 12 |
| 6 | Ali Zeaiter | Roche (Switzerland) | 11 |
| 7 | Anne‐Marie C. Dingemans | Erasmus MC Cancer Institute | 11 |
| 8 | Sai‐Hong Ignatius Ou | University of California, Irvine | 11 |
| 9 | James Chih‐Hsin Yang | National Taiwan University Hospital | 8 |
| 10 | Elena Guerini | Roche (Switzerland) | 7 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer | 2017 | 2490 | Lung Cancer Diagnosis and Treatment |
| Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial | 2017 | 921 | Lung Cancer Diagnosis and Treatment |
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study | 2014 | 696 | Lung Cancer Treatments and Mutations |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial | 2015 | 641 | Lung Cancer Diagnosis and Treatment |
| CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant | 2011 | 633 | Lung Cancer Treatments and Mutations |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular weight of Alecensa?
Which organizations hold the most patents related to Alecensa?
What are the primary research topics associated with Alecensa?
Who are the most prolific authors publishing on Alecensa research?
How has research and patent activity around Alecensa evolved in recent years?